Welcome to the Healthy Longevity Center.

We are honored to partner with you in your health journey. Our mission is to help patients maintain health, independence, and well-being over time through comprehensive, medically grounded care. From your first visit forward, our team is here to listen, guide, and support you with personalized attention and clear, compassionate care.

About Dr. Dong Wang, M.D.

Dr. Dong Wang’s remarkable career in neurology is distinguished by his extensive post-doctoral training, research contributions, and commitment to patient care. His significant research output, particularly in Glut-Deficiency Syndrome and Pyruvate Carboxylase Deficiency, highlights his dedication to advancing understanding and treatment options for these complex neurological conditions. With more than 30 original research papers published in reputable journals, Dr. Wang has established himself as a leading authority in these areas of neurology.

Dementia / Alzheimer’s

The Healthy Longevity Center is dedicated to serving patients and providing them with pioneering options to treat conditions such as dementia and Alzheimer’s. We are excited to be able to offer access to the TB006 medication, which offers immense hope for millions of individuals and their families affected by the debilitating condition of dementia.

Understanding TB006

TB006 is an investigational drug for the treatment of Alzheimer’s disease/dementia, which has shown promising safety and preliminary efficacy in a Phase IIa clinical trial.

Clinical Evidence & Trial Outcomes

The Phase 1b/2a trial for TB006 demonstrated significant improvements in cognition and function in patients with mild dementia after one month of treatment.

In the trial, there were improvements in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) for most patients

This suggests a potential slowing or reduction of clinical decline.

In the OLE trial, nearly half of the patients treated with TB006 for three months or longer exhibited some level of cognitive improvement.

Expanded Access Program

Based on these positive results, the drug has been approved for inclusion in the Expanded Access Program (EAP) to meet the urgent treatment needs of some severely affected patients.

Treatment Plan

Treatment Process

To learn more about getting started, initial evaluation, application review, treatment program and see if you qualify, learn more

Learn More

Eligibility

To be eligible for the medication, patients must have a diagnosis of mild, moderate, or moderate-to-severe Alzheimer’s/dementia, and other health conditions must be well controlled and stable. Patients cannot be receiving other Alzheimer’s drug treatments, and must complete the initial evaluation with testing. We invite you to complete a HIPAA-compliant eligibility form to complete pre-screening to see if patients will qualify for this process. Once submitted, our team will review your information and follow up directly with next steps.

Safety Monitoring

To learn more about Safety Monitoring click learn more

Learn More

Frequently Asked Questions (FAQ)

Are there any ongoing clinical trials for TB006?

TrueBinding has completed patient enrollment for the Phase Ib/II clinical trial and the open-label extension (OLE) study of TB006 for Alzheimer’s disease. Currently, there are no actively recruiting clinical trials for TB006. This Expanded Access Program ensures continued patient access to this breakthrough therapy until the next trial phase begins.

What is an Expanded Access Program?

Expanded Access, also known as compassionate use, is a regulatory pathway that allows patients with serious or life-threatening conditions to access investigational drugs outside of clinical trials. It is intended for patients who have exhausted approved treatment options or are unable to participate in clinical trials, providing a humanitarian avenue to promising therapies not yet fully approved by the FDA.

View EAP

Does participating in this program require payment?

Currently, participation in the TB006 Expanded Access Program requires bearing relevant costs. Due to the high research, development, and production expenses of TB006, in addition to the cost of the drug itself, you will also be responsible for the following expenses: physician consultation fees, as well as out-of-pocket portions of laboratory tests and other assessments required for monitoring treatment progress. As a patient enrolled in this program, you will need to cover the costs of the medication, along with examinations, treatments, and related medical expenses not covered by insurance.